1
ALL1
Neurocrine BiosciencesYear
1
ALL1
2022DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
U.S.A1
ALL1
Not ApplicableTherapeutic Area
1
ALL1
NeurologyStudy Phase
1
ALL1
UndisclosedDeal Type
0
ALLProduct Type
1
ALL1
Small moleculeDosage Form
0
ALLLead Product
1
ALL1
BenztropineTarget
1
ALL1
Muscarinic M1 receptorLead Product(s) : Benztropine
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Benztropine is an anticholinergic medication approved as an adjunct for treatment of all forms of parkinsonism, including drug-induced parkinsonism that causes movement problems similar to those seen in Parkinson's disease, such as tremors, slow movement...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2022
Lead Product(s) : Benztropine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable